

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P. Dex 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/002,712	. 11/01/2001	James J. Hartman	CYTOP035C4	3093	
20350 7	590 07/11/2003				
	AND TOWNSEND	EXAMINER			
EIGHTH FLO	RCADERO CENTER OOR SISCO, CA 94111-3834		GITOMER, RALPH J		
			ART UNIT	PAPER NUMBER	
			1651		
			DATE MAILED: 07/11/2003	7	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. 10/002,712

Applicant(s)

Hartman et al.

Office Action Summary

Examiner Ralph Gitomer Art Unit 1651 •

The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the						
mailing date of this communication.						
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (8) MONTHS from the mailing date of this communication.						
- Any rep	to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	ne application to become his communication, ev	ne ABANDt ren if timely	บทยบ (35 U.S.U. 9 133). • filed, may reduce any		
earned p						
1) 💢	Responsive to communication(s) filed on Nov 1, 20			· · · · · · · · · · · · · · · · · · ·		
	This action is FINAL. 2b) ☑ This acti					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.						
Dispositi	ion of Claims					
4) 💢	Claim(s) <u>18-27</u>			is/are pending in the application.		
4	a) Of the above, claim(s)					
	Claim(s)					
	Claim(s) <u>18-27</u>					
	Claim(s)					
	Claims					
	tion Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)□	The standard of the standard o					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)	The proposed drawing correction filed on			approved b) \square disapproved by the Examiner.		
	If approved, corrected drawings are required in reply to	to this Office ac	tion.			
12) 🗆	The oath or declaration is objected to by the Exami	iner.				
Priority under 35 U.S.C. §§ 119 and 120						
	13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some* c) None of:						
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No.					
 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).						
a) The translation of the foreign language provisional application has been received.						
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachm						
	otice of References Cited (PTO-892)	4) Interview Su	ımmary (PT	(O-413) Paper No(s)		
2) No	otice of Draftsperson's Patent Drawing Review (PTO-948)	-	formal Pate	nt Application (PTO-152)		
3) X Information Disclosure Statement(s) (PTO-1449) Paper No(s). 4 6) Other:						

Serial No. 10/002,712 Art Unit 1651

The amendments received 11/1/2001 and the IDS received 1/28/2002 have been entered and claims 18-27 are currently pending in this application. Please inform the examiner of any related applications, abandoned, allowed or pending.

On page 17 Example 2 of the present specification is directed to isolating and polymerizing G-actin from muscle tissue. It would appear the presently cited references teach only methods of isolating and polymerizing F-actin from muscle tissue. On page 8 of the present specification, last paragraph, is directed to isolating and polymerizing actin in general, of no specific type. Please clarify that the intended and claimed invention is distinct from isolating and purifying actin or F-actin and how it is different.

The Petition under 37 CFR 1.48(b) deleting Malik, Sakowicz and Finer as inventors is acceptable.

In view of the papers filed 4/22/3003, it has been found that this nonprovisional application, as filed, through error and without deceptive intent, improperly set forth the inventorship, and accordingly, this application has been corrected in compliance with 37 CFR 1.48(c). The inventorship of this application has been changed by the addition of Vaisberg and Spudich.

5

10

15

20

-3-

Serial No. 10/002,712 Art Unit 1651

The application will be forwarded to the Office of Initial Patent Examination (OIPE) for issuance of a corrected filing receipt, and correction of the file jacket and PTO PALM data to reflect the inventorship as corrected.

5

Claims 18-27 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Each of the following applies in all occurrences.

Claim 18 is directed to purifying actin but lacks a step to recover a product. In claim 20 magnesium is used but the claim does not state how it is used.

15

10

The title of the invention is not aptly descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

20

The Abstract of the Disclosure is objected to because it is not directed to the claimed invention. Correction is required. See M.P.E.P. § 608.01(b).

-4-

Serial No. 10/002,712 Art Unit 1651

The following prior art pertinent to applicant's disclosure is made of record and not relied upon:

Hartman (6,495,337, 6,509,167 and 2002/0022716 A1) may be related cases.

Pardee (Methods in Cell Biology) teaches purification of G-actin.

Kobayashi (Biochimica et Biophysica Acta) teaches F-actin

purification.

Gonsior (J of Muscle Research and Cell Motility) teaches G-actin purification.

Ebashi (J Biochem) teaches purifying F-actin.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ralph Gitomer whose telephone number is (703) 308-0732. The examiner can normally be reached on Tuesday-Friday from 8:00 am - 5:00 pm. The examiner can also be reached on alternate Mondays. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on (703) 308-4743. The fax phone number for this Art Unit is (703) 308-4556. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235. For 24 hour access to patent application information 7 days per week, or for filing

20

5

10

15

-5-

Serial No. 10/002,712 Art Unit 1651

applications electronically, please visit our website at www.uspto.gov and click on the button *Patent Electronic Business Center* for more information.

Railones

Ralph Gitomer
Primary Examiner
Group 1651

RALPH GITOMER PRIMARY EXAMINER GROUP 1200

5

10